KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Net Cash Flow (2016 - 2026)

Bio-Rad Laboratories has reported Net Cash Flow over the past 18 years, most recently at -$29.1 million for Q1 2026.

  • Quarterly Net Cash Flow fell 182.91% to -$29.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$4.9 million through Mar 2026, down 105.79% year-over-year, with the annual reading at $59.3 million for FY2025, 22.18% down from the prior year.
  • Net Cash Flow was -$29.1 million for Q1 2026 at Bio-Rad Laboratories, down from $134.0 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $324.7 million in Q1 2022 and troughed at -$212.5 million in Q2 2022.
  • The 5-year median for Net Cash Flow is $11.9 million (2024), against an average of $2.1 million.
  • The largest YoY upside for Net Cash Flow was 1710.06% in 2022 against a maximum downside of 471.66% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at -$65.5 million in 2022, then rose by 27.71% to -$47.4 million in 2023, then surged by 242.47% to $67.5 million in 2024, then skyrocketed by 98.52% to $134.0 million in 2025, then crashed by 121.72% to -$29.1 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Net Cash Flow are -$29.1 million (Q1 2026), $134.0 million (Q4 2025), and $25.4 million (Q3 2025).